MEDIA ADVISORY --- BIO CEO & Investor Conference 2002: Highlights for Thursday, February 21, 2002

  • Contact: Carrie Housman, BIO, 202-345-3677, chousman@bio.org
    Ashley Myler, SheaHedges Group, 703-3
  • Recommend
  • Tweet
  • Print
  • Email

Where: Waldorf=Astoria Hotel, New York

9:30 - 10:30 a.m.
Press Conference
Herbert Hoover Room
Accenture Press Conference - Accenture will hold a press conference to announce a major new alliance in the drug discovery arena.

10:40 a.m. - 12:00 p.m.
Investor Session 7
Jade Room
Cystostatics & Cancer: Are We Entering a New Era in Cancer Treatment? - This panel will discuss current trends in oncology treatment, the new oncology market and cancer prevention.

10:40 a.m. - 12:00 p.m.
Investor Session 8
Astor Room
The Biotech Mosaic: Putting The Pieces In Place - Panelists will share their expertise in structuring partnerships that fit a biotech company's strategic goals.

10:40 a.m. - 12:00 p.m.
CEO Roundtable 7
East Foyer
Finding and Licensing Late-Stage Products - This roundtable will discuss various strategies for finding the right products to in-license, structuring clinical-stage product deals to minimize overall risk and devising creative ways to finance the deal.

12:00 - 1:40 p.m.
LUNCHEON
Grand Ballroom
Helix Awards. Keynote Speaker, Michael Waldholz, Medical Writer, Wall Street Journal

1:40 - 3:00 p.m.
Investor Session 9
Jade Room
Gene Therapy: The Future of Protein Delivery - Panelists from clinical-stage gene therapy companies will discuss this technology, now approaching commercialization.

1:40 - 3:00 p.m.
Investor Session 10
Astor Room
Monoclonal Antibody Therapeutics: The Future Looks Promising - This panel will discuss the market for these therapies and where the investments opportunities are today.

1:40 - 3:00 p.m.
CEO Roundtable 8
East Foyer
Building a Fully Integrated Biopharmaceutical Company - This roundtable will examine the pros and cons of building a fully integrated biopharmaceutical company and the various strategies used by companies to refocus operations on drug development, build the necessary product and technology portfolios, and ultimately increase shareholder value.

3:10 - 4:30 p.m.
Investor Session 11
Jade Room
The Next Generation of Cancer Therapeutics - This panel will help investors understand both near-term and long-term investment opportunities in this sector.

3:10 - 4:30 p.m.
Investor Session 12
Astor Room
Discovery Chemistry and the Development of Small Molecules - This panel will explore the value of chemistry in the drug discovery process and new trends and technology that may break the bottleneck created by the flood of new targets.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit www.bio.org.

###

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.